Page 336 - Read Online

Archakova et al. Vessel Plus 2018;2:34 I http://dx.doi.org/10.20517/2574-1209.2018.52 Page 9 of 10

30. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed
tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation 1995;92:2157-62.
31. Ribeiro S, Ramos A, Brandão A, Rebelo JR, Guerra A, et al. Cardiac valve calcification in haemodialysis patients: role of calcium-
phosphate metabolism. Nephrol Dial Transplant 1998;13:2037-40.
32. Kalpakian MA, Mehrotra R. Vasgular calcification and disordered mineral metabolism in dialysis patients. Semin Dial 2007;20:139-43.
33. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, et al. Cardiac calcification in adult hemodialysis patients. A link between end-
stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
34. Bhan I, Thadhani R. Vascular calcification and ESRD: a hard target. Clin J Am Soc Nephrol 2009; doi: 10.2215/CJN.04800709.
35. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, et al. Electron beam computed tomography in the evaluation of cardiac
calcification in chronic dialysis patients. Am J Kidney Dis 1996;27:394-401.
36. Komaba H, Igaki N, Takashima M, Goto S, Yokota K, et al. Calcium, phosphorus, cardiovascular events and all-cause mortality in
hemodialysis patients: a single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy
guidelines. Ther Apher Dial 2008;12:42-8.
37. Bellasi A, Ferramosca E, Ratti C, Block G, Raggi P. Cardiac valve calcification is a marker of vascular disease in prevalent hemodialysis
patients. J Nephrol 2012;25:211-8.
38. Lee CT, Chua S, Hsu CY, Tsai YC, Ng HY, et al. Biomarkers associated with vascular and valvular calcification in chronic hemodialysis
patients. Dis Markers 2013;34:229-35.
39. Volkov MM, Degtereva OA, Shevyakova EV. Factors associated with calcification of valvular heart apparatus in patients on chronic
hemodialysis. Available from: https://cyberleninka.ru/article/n/faktory-svyazannye-s-kaltsinatsiey-klapannogo-apparata-serdtsa-u-
patsientov-na-hronicheskom-gemodialize. [Last accessed on 24 Oct 2018] (in Russian)
40. Cheng CY, Kuro-o M, Razzaque MS. Molecular regulation of phosphate metabolism by fibroblast growth factor-23- klotho system. Adv
Chronic Kidney Dis 2011;18:91-7.
41. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal
phosphate wasting. J Clin Invest 2003;112:683-92.
42. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate
homeostasis. J Bone Miner Res 2004;19:429-35.
43. Volgina G, Shtandel V, Balkarova O, Lovchinsky E. Hyperphosphatemia in chronic kidney disease: modern correction strategy. Vrach
2012;7:19-23. (in Russian)
44. Milovanova LY, Milovanov YS, Kozlovskaya LV, Mukhin NA. New markers of cardiorenal interrelations in chronic kidney disease.
Therapeutic Archives 2013;6:17-24. (in Russian)
45. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with
increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009;24:2792-6.
46. Grabner A, Schramm K, Silswal N, Hendrix M, Yanucil C, et al. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. Sci
Rep 2017;7:1993.
47. Inaba M, Okuno S, Imanishi Y, Yamada S, Shioi A, et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-
diabetic and diabetic hemodialysis patients. Osteoporos Int 2006;17:1506-13.
48. Chan GC, Divers J, Russell GB, Langefeld CD, Wagenknecht LE, et al. FGF23 concentration and APOL1 genotype are novel predictors
of mortality in African Americans with type 2 diabetes. Diabetes Care 2018;41:178-86.
49. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, et al. Fibroblast growth factor 23 and mortality among patients
undergoing hemodialysis. N Engl J Med 2008;359:584-92.
50. Suliman ME, Stenvinkel P, Bárány P, Heimbürger O, Anderstam B, et al. Hyperhomocysteinemia and its relationship to cardiovascular
disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. Am J Kidney Dis 2003;41:S89-95.
51. Kardami E, Jiang ZS, Jimenez SK, Hirst CJ, Sheikh F, et al. Fibroblast growth factor 2 isoforms and cardiac hypertrophy. Cardiovasc
Res 2004;63:458-66.
52. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, et al. Serum phosphate levels and mortality risk among people with
chronic kidney disease. J Am Soc Nephrol 2005;16:520-8.
53. Munoz Mendoza J, Isakova T, Cai X, Bayes LY, Faul C, et al. Inflammation and elevated levels of fibroblast growth factor 23 are
independent risk factors for death in chronic kidney disease. Kidney Int 2017;91:711-9.
54. Rahman A, Gibney L, Person SD, Williams OD, Kiefe C, et al. Validity of self-reports of reasons for hospitalization by young adults
and risk factors for discordance with medical records: the coronary artery risk development in young adults (CARDIA) study. Am J
Epidemiol 2005;162:491-8.
55. Coen G, Manni M, Mantella D, Pierantozzi A, Balducci A, et al. Are PTH serum levels predictive of coronary calcifications in
haemodialysis patients? Nephrol Dial Transplant 2007;22:3262-7.
56. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004;15:2959-64.
57. Freedman BI, Divers J, Russell GB, Palmer ND, Bowden DW, et al. Plasma FGF23 and calcified atherosclerotic plaque in african
americans with type 2 diabetes mellitus. Am J Nephrol 2015;42:391-401.
58. Lanzer P, Boehm M, Sorribas V, Thiriet M, Janzen J, et al. Medial vascular calcification revisited: review and perspectives. Eur Heart J
2014;35:1515-25.
59. Ishimura E, Okuno S, Kitatani K, Kim M, Shoji T, et al. Different risk factors for peripheral vascular calcification between diabetic and